ZIOPHARM Oncology Inc. (ZIOP) Inks Collaboration Deal with Solasia for Pan-Asia/Pacific Commercialization

QualityStocks would like to highlight ZIOPHARM Oncology (NASDAQ: ZIOP), an oncology small molecule and synthetic biology drug development company, engaged in the development and commercialization of a diverse portfolio of cancer therapeutics. The company is currently focused on several clinical programs.
In the company’s news yesterday,

ZIOPHARM Oncology has entered into a license and collaboration agreement with Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, in which the two companies will develop and commercialize ZIOPHARM’s darinaparsin product (Zinapar™ or ZIO-101) and related organic arsenic molecules in specified Pan-Asian/Pacific territories.

Darinaparsin is being developed for the treatment of various hematologic and solid cancers, and was granted Orphan Drug Designation in the U.S. and Europe. Per today’s agreement, Solasia intends to seek similar status in Japan.

The agreement gives Solasia an exclusive license to develop and commercialize darinaparsin in intravenous and oral forms, as well as related organic arsenic indications for human use in Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand.

“We are very excited to add darinaparsin to our growing pipeline of oncology drugs. Cancer is a leading cause of death in Asia, with hematologic malignancies increasing as a subset of the total cancer incidence rate,” Steven E. Engen, president and CEO of Solasia stated in the press release. “Darinaparsin is well tolerated and is expected to be less toxic than arsenics commonly used in Japan, China and other territories in Asia and has demonstrated promising efficacy in hematologic cancers, including peripheral T-cell lymphoma (PTCL), a disease nearly twice as prevalent in Asia compared to the West, but for which there are very few treatment options. We look forward to working with ZIOPHARM in developing this novel drug, and to filling this growing unmet medical need in Asia.”

ZIOPHARM will receive an up-front payment of $5 million, which is allotted exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory. The company will also be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones. In addition, ZIOPHARM will be entitled to receive double-digit royalty payments from Solasia on net sales of licensed products in the applicable territories, once commercialized, and a percentage of any sublicense revenues generated by Solasia.

“This agreement marks an important milestone for our darinaparsin program, as it provides validation for the compound’s clinical potential as well as additional support ahead of moving into the pivotal phase later this year,” Jonathan Lewis, M.D., Ph.D., CEO and chief medical officer of ZIOPHARM stated. “Solasia is a strong partner whose management and advisory team are highly experienced in the development and commercialization of products within these territories.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.